BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is developing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, addressing growing demand for faster, scalable and noninvasive impairment detection across workplace safety, healthcare and public safety markets. By leveraging speech as a diagnostic biomarker, the company is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and Butterfly Network Inc. (NYSE: BFLY).

As substance-use patterns evolve and the limitations of traditional testing methods become increasingly apparent, AI-enabled diagnostics are gaining momentum as a potential next-generation solution for real-time decision-making and risk management. MindBio is targeting large commercial opportunities spanning workplace compliance, telehealth and consumer health applications, positioning its voice-based platform within a broader transformation toward accessible, data-driven diagnostic technologies.

To view the full press release, visit https://ibn.fm/BZOb2

About MindBio Therapeutics Corp.

MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…

14 hours ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…

4 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…

4 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

6 days ago